Albert Bourla, Pfizer CEO (Lintao Zhang/Getty Images)
May 2, 2023 09:58 AM EDTUpdated 01:24 PM
R&D
Pharma

Pfiz­er culls some Are­na-ac­quired pro­grams as it looks to­ward new launch­es

Kyle LaHucik

Senior Reporter

As Pfiz­er works to con­sum­mate a mega-merg­er with Seagen to prop up its on­col­o­gy pipeline and prod­uct port­fo­lio, the Big Phar­ma dis­closed some pipeline …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times